Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders
Latest Information Update: 09 Feb 2021
At a glance
- Drugs Tafluprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Santen Pharmaceutical
- 09 Feb 2021 New trial record